<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03245333</url>
  </required_header>
  <id_info>
    <org_study_id>GenSci 030 CT-III</org_study_id>
    <nct_id>NCT03245333</nct_id>
  </id_info>
  <brief_title>A Study of Recombinant Human Growth Hormone Injection for Short Children With Small for Small for Gestational Age(SGA)</brief_title>
  <official_title>Phase Ⅲ Clinical Study of Recombinant Human Growth Hormone Injection (JINTOPIN AQ) for Short Children With Small for Gestational Age(SGA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneScience Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Children's Hospital of Zhejiang University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GeneScience Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to the results of the phase II study, choose the best dose of JINTOPIN AQ for short
      SGA children, further to evaluate the efficacy and safety of the treatment of short SGA
      children.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of height standard deviation score for chronological age (△Ht SDSCA)</measure>
    <time_frame>52 weeks</time_frame>
    <description>△Ht SDS= Ht SDSafter treatment - Ht SDSbaseline Ht SDSCA = (height - reference mean for CA) / reference SD for CA (refers to the height value at particular timepoint )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Height（Ht）at the end of treatment</measure>
    <time_frame>Stage 1：52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height（Ht）at the end of treatment</measure>
    <time_frame>Stage 2：Every 52 weeks, up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized height velocity (HV)</measure>
    <time_frame>Stage 1：52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized height velocity (HV)</measure>
    <time_frame>Stage 2：Every 52 weeks, up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone age maturation</measure>
    <time_frame>Stage 1：52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone age maturation</measure>
    <time_frame>Stage 2：Every 52 weeks, up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mole ratio of IGF-1 and IGFBP-3</measure>
    <time_frame>Stage 1：52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mole ratio of IGF-1 and IGFBP-3</measure>
    <time_frame>Stage 2：Every 52 weeks, up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGF-1 standard deviation score (SDS)</measure>
    <time_frame>Stage 1：52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGF-1 standard deviation score (SDS)</measure>
    <time_frame>Stage 2：Every 52 weeks, up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Small for Gestational Age Infant</condition>
  <arm_group>
    <arm_group_label>Stage 1-experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JINTOPIN AQ 0.2IU/kg/d（0.46mg/kg /wk）, for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1-negative control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>observed only for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2-experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After completing the stage 1, experimental groups is administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd week to the final height.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2-negative control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>After completing the stage 1, negative control groups is administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd week to the final height.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human Growth Hormone Injection</intervention_name>
    <description>Stage 1：JINTOPIN AQ 0.2IU/kg/d（0.46mg/kg /wk）for 52 weeks.</description>
    <arm_group_label>Stage 1-experimental group</arm_group_label>
    <arm_group_label>Stage 1-negative control</arm_group_label>
    <arm_group_label>Stage 2-experimental group</arm_group_label>
    <arm_group_label>Stage 2-negative control</arm_group_label>
    <other_name>rhGH Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human Growth Hormone Injection</intervention_name>
    <description>Stage 2: After completing phase 1, patients are administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd weeks to the final height.</description>
    <arm_group_label>Stage 1-experimental group</arm_group_label>
    <arm_group_label>Stage 1-negative control</arm_group_label>
    <arm_group_label>Stage 2-experimental group</arm_group_label>
    <arm_group_label>Stage 2-negative control</arm_group_label>
    <other_name>rhGH Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of full-term small for gestational age, SGA.

          -  Chronological age between 2-6.5 years in girls and 2-7.5 years in boys. Both genders.

          -  Prepubertal stage (Tanner I).

          -  Height was lower than the mean -2SD of the values of normal children of the same age
             and gender when participating in the study.

          -  A GH peak concentration ＞10µg/L in a provocative test within a year before
             participating in the study.

          -  Bone age＜Chronological age+1.

          -  Normal glucose regulation：Fasting blood-glucose &lt; 5.6mmol/L, and 2 hours postprandial
             blood-glucose &lt; 7.8mmol/L.

          -  Gestational age was 37 to 42 weeks.

          -  The subjects and their guardians signed informed consent.

        Exclusion Criteria:

          -  Subjects with Liver and renal insufficiency (ALT &gt; 1.5 times of upper limit of normal
             value, Cr&gt; upper limit of normal value).

          -  Patients are positive for antibodies to hepatitis B core (HBc), hepatitis B surface
             antigen (HBsAg) or hepatitis B e antigen (HBeAg).

          -  Known Highly allergic constitution or allergic to the test drug.

          -  Subjects with diabetes, severe cardiopulmonary and pulmonary disease, and
             hematological diseases, malignant tumors, or systemic infection, immunocompromised
             patients and patients with psychosis.

          -  Subjects with other growth disorders, such as Turner syndrome, constitutional delay of
             growth and puberty, and Laron syndrome and growth hormone receptor deficiency.

          -  Subjects who have received the treatment of GH.

          -  Subjects took part in other clinical trial study within 3 months.

          -  Children who have treated with other hormone (such as gonadal hormone and
             glucocorticoids etc, continuous administration of more than a month) and that may
             affect growth hormone secretion or action including oxygen male dragon, growth hormone
             releasing hormone, etc. within 3 months.

          -  Other conditions which in the opinion of the investigator preclude enrollment into the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaohua Feng</last_name>
    <phone>0431-85170552</phone>
    <email>fengxiaohua@gensci-china.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaoping Luo</last_name>
    <phone>+86-27-83663712</phone>
    <email>xpluo@tjh.tjmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The first affiliated Hospital with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Children's Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shanghai Children's Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2017</study_first_submitted>
  <study_first_submitted_qc>August 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2017</study_first_posted>
  <last_update_submitted>December 10, 2017</last_update_submitted>
  <last_update_submitted_qc>December 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

